Sanofi Gets Approval For SU-type Amaryl ODTs
This article was originally published in PharmAsia News
Sanofi announced Aug. 16 it received approval for sulphonylurea oral hypoglycemic agent Amaryl (glimepiride) for Type II diabetes in 0.5mg orally disintegrating tablets.
You may also be interested in...
Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces
Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.